A new-drug application was filed with the FDA by Janssen Biotech for apalutamide, which is being developed as a treatment for men with nonmetastatic castration-resistant prostate cancer. A late-stage study showed a statistically significantly extension of metastasis-free survival in patients who use apalutamide versus placebo.
Janssen seeks FDA approval of prostate cancer drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.